Ambrx has presented new results on their lead program ARX788, a homogeneous and highly stable, site-specific antibody drug conjugate targeting HER2 positive cancers. "[...] Phase 1 studies demonstrated promising antitumor activity in heavily pre-treated cancer patients at the recommended Phase 2 dose", said Joy Yan, MD, PhD, Ambrx Chief Medical Officer. The randomized controlled Phase 2/3 has treated 22 subjects and continues to enroll patients quickly. Yourway is delighted about the positive results and continues to support the fight against cancer.